Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Triple Negative Breast Cancer Clinical Trial

Official title:

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03281954
• Other study ID #: NSABP B-59/GBG 96-GeparDouze
• Secondary ID: 2017-002771-25MO
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: December 19, 2017
• Est. completion date: November 30, 2027

Study information

• Verified date: April 2024
• Source: NSABP Foundation Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a drug that looks like the study drug but contains no medication.) The usual chemotherapy in this study is paclitaxel (WP) and carboplatin followed by doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple negative breast cancer, no additional treatment is given unless the cancer returns. This study will also look at continuing treatment after surgery with atezolizumab or the placebo. To be better, atezolizumab given with the neoadjuvant therapy should be better at: 1) decreasing the amount of tumor in the breast than the placebo given with the usual chemotherapy and 2) decreasing the chance of the cancer from returning after surgery.

Another purpose of this study is to test the good and bad effects of atezolizumab when added to the usual chemotherapy. Atezolizumab may keep your cancer from growing but it can also cause side effects.

Description:

NSABP B-59/GBG 96-GeparDouze is a prospective, randomized, double-blind, Phase III clinical trial. This is a collaborative study being conducted by NSABP Foundation, Inc. in partnership with the German Breast Group (GBG), and supported by funding by Genentech, a Member of the Roche Group, and F. Hoffmann-La Roche, Ltd.

In this clinical trial of neoadjuvant and adjuvant administration of atezolizumab/placebo in patients with high risk triple-negative breast cancer, the potential incremental efficacy and safety of neoadjuvant administration of atezolizumab/placebo with a sequential regimen of weekly paclitaxel with every-3-week carboplatin followed immediately by neoadjuvant administration of atezolizumab/placebo with AC/EC will be evaluated. Patients will then undergo surgery. Following recovery from surgery, patients will initiate approximately 6 months of adjuvant therapy with atezolizumab/placebo and receive the same investigational agent they received pre-operatively. Administration of radiation therapy will be based on local standards at the discretion of patients and investigators, but if administered, atezolizumab/placebo will be administered concurrently. Adjuvant atezolizumab/placebo may be delayed until after completion of radiation therapy per investigator discretion. Patients with residual invasive cancer at the time of surgery may receive capecitabine concurrently with atezolizumab/placebo in the adjuvant setting per investigator discretion and local guidelines. Patients with germline BRCA1 or BRCA2 mutations with residual invasive cancer at the time of surgery may receive olaparib in the adjuvant setting per investigator discretion and local guidelines. Patients receiving olaparib must discontinue atezolizumab/placebo.

The primary aims of the study are 1) to determine value of atezolizumab in improving pathologic complete response in the breast and post-therapy lymph nodes evaluated histologically (pCR breast and nodes [(ypT0/Tis ypN0)]), and 2) to determine the value of atezolizumab in improving event-free survival (EFS). Secondary aims include: pathologic complete response in the breast (ypT0/Tis); pathologic complete response in the breast and lymph nodes (ypT0 ypN0); positive nodal status conversion rate; overall survival; recurrence-free interval: distant disease-free survival; brain metastases free survival; and toxicity. The stratification factors for the study are: 1) clinical size of the primary tumor (1.1-3.0 cm; > 3.0 cm); 2) nodal status as determined by protocol-specified criteria (negative, positive); 3) AC/EC (every 2 weeks; every 3 weeks); and 4) Region (North America; Europe).

For patient eligibility, local testing on the diagnostic core must have determined the patient's tumor to be ER-negative, PgR-negative, and HER2-negative by current ASCO/CAP guidelines. Material from either the diagnostic core biopsy or the research biopsy must be sent for central testing for confirmation of ER, PgR, and HER2 to confirm eligibility. If local testing has determined a tumor to be HER2 equivocal or to have a borderline ER/PgR status (% IHC staining < 10% for both), material may be submitted for central testing to determine eligibility.

In order to proactively identify and further assess any cardiac toxicity that may occur with the combination of anthracyclines and atezolizumab, this study includes a cardiac safety lead-in for the first 60 patients who initiate AC/EC. The safety lead-in will consist of assessment of ECG and serum troponin-T obtained just prior to administration of the first dose of AC/EC, following completion of the administration of the 1st and 3rd cycle of AC/EC prior to initiation of the atezolizumab/placebo. An additional assessment of LVEF with echocardiogram or MUGA scan will also be obtained prior to the 3rd dose of AC/EC. In order to provide an early assessment of cardiac safety, results of the troponin-T assessments, ECGs, LVEF assessment, and cardiac safety data will be evaluated by the Data Safety Monitoring Board (DSMB) when the last of the initial 20 patients who initiate AC/EC undergo their scheduled post-surgery LVEF assessment. When the last of the first 60 patients to initiate AC/EC undergo their scheduled post-surgery LVEF assessment, results of the troponin assessments, ECGs, LVEF assessments, and cardiac safety data from all 60 patients will be evaluated by the DSMB.

Research core biopsies of breast primary at baseline and 1-4 days prior to the second dose of atezolizumab/placebo are a study requirement for all patients. One to three representative blocks of residual primary tumor containing the maximum amount of tumor and node with the largest focus of metastasis is required from the definitive breast surgery if gross residual disease is greater than or equal to 1.0 cm. If gross residual disease is less than 1.0 cm, tissue should be submitted, if possible. Blood specimens will be collected on all patients at baseline for exploratory biomarker analysis and to support future correlative studies.

Accrual to NSABP B-59/GBG 96-GeparDouze began in December 2017 and was completed in May 2021 with a total of 1550 patients randomized. Based on actual accrual and the decision to eliminate pCR as a co-primary endpoint, we recalculated the power to detect a hazard ratio of 0.70 attributed to the addition of atezolizumab, assuming a lost-to-follow-up rate of 0.00083 per month, using the actual accrual pattern for the power calculation. With 1550 patients accrued in 42 months, an additional 22 months follow up will allow us to obtain 252 events under the assumptions stated above, which will provide 80% power to detect a HR of 0.7 between the atezolizumab and the placebo arm at an overall 2-sided alpha level of 0.05.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1550
• Est. completion date: November 30, 2027
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The patient must have consented to participate and, prior to beginning specific study procedures, must have signed and dated an appropriate IRB-approved consent form that conforms to federal and institutional guidelines for study treatment and for submission of tumor samples from a research biospy as required by NSABP B-59/GBG 96-GeparDouze for baseline correlative science studies.

• The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy.

• Local testing on the diagnostic core must have determined the tumor to be ER-negative, PgR-negative, and HER2-negative by current ASCO/CAP guidelines. (If local testing has determined a tumor to be HER2 equivocal or to have a borderline ER/PgR status (% IHC staining < 10% for both) and other eligibility criteria are met, material may be submitted for central testing to determine eligibility.)

• Central testing for ER, PgR, and HER2 will be performed, and the tumor must be determined to be ER-negative, PgR-negative, and HER2-negative by current ASCO/CAP Guidelines Recommendations.

• The tumor specimen used for central ER, PgR, and HER2 testing must also be used for central testing of PD-L1 status using the Ventana PD-L1 testing result including PD-L1 indeterminate Patients will be classifies as positive, negative, or indeterminate for stratification purposes.

• Patients must be = 18 years old.

• Patient may be female or male.

• The ECOG performance status must be 0-1.

• The primary tumor can be clinical stage T2 or T3, if clinically node negative according to AJCC 7th Edition. If the regional lymph nodes are cN1 and cytologically or histologically positive or cN2-N3 with or without a biopsy, the primary breast tumor can be clinically T1c, T2, or T3.

• Ipsilateral axillary lymph nodes must be evaluated by imaging (mammogram, ultrasound, and/or MRI) within 84 days prior to study entry. If suspicious or abnormal, FNA or core biopsy is recommended. Findings of these evaluations will be used to define the nodal status prior to study entry according to the following criteria:

• Nodal status - negative (Imaging of the axilla is negative; Imaging is suspicious or abnormal but the FNA or core biopsy of the questionable node[s] on imaging is negative)

• Nodal status - positive (FNA or core biopsy of the node[s] is cytologically or histologically suspicious or positive; Imaging is suspicious or abnormal but FNA or core biopsy was not performed.)

• Patients with synchronous bilateral or multicentric HER2-negative breast cancer are eligible as long as the highest risk tumor is ER-negative and PgR-negative and meets stage eligibility criteria. All of the other invasive tumors must also be HER2-negative by ASCO/CAP Guidelines based on local testing. Central testing to confirm TNBC status is only required for the highest risk tumor.

• Blood counts performed within 28 days prior to randomization must meet the following criteria:

• ANC must be = 1500/mm3;

• platelet count must be = 100,000/mm3; and

• hemoglobin must be =10 g/dL.

• The following criteria for evidence of adequate hepatic function performed within 28 days prior to randomization must be met:

• total bilirubin must be = ULN for the lab unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and

• alkaline phosphatase must be = 2.5 x ULN for the lab; and

• AST and ALT must be = 1.5 x ULN for the lab.

• Patients with AST or ALT or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (CT, MRI, abdominal ultrasound, PET-CT, or PET scan) performed within 28 days prior to randomization does not demonstrate metastatic disease and the requirements in criterion (just above) are met.

• Patients with alkaline phosphatase that is > ULN but less than or equal to 2.5 x ULN or with unexplained bone pain are eligible for inclusion in the study if bone imaging (bone scan, PET-CT scan, or PET scan) supported by additional studies when indicated (CT, x-ray, MRI) performed within 28 days prior to randomization does not demonstrate metastatic disease.

• Patients with N2 or N3 nodal disease or T3 primary disease must undergo liver and bone imaging (as described in 4.1.13 and 4.1.14) within 28 days prior to randomization, irrespective of baseline lab results, and studies must not demonstrate metastatic disease. Chest imaging with chest x-ray PA and Lateral, CT of the chest, or PET-CT must also be performed.

• Creatinine clearance = 50 mL/min (see Section 7.2.1 for instructions regarding calculation of creatinine clearance) performed within 28 days prior to randomization.

• PT/INR = ULN within 28 days of randomization. Patients receiving therapeutic anti-coagulants are not eligible.

• A serum TSH and AM (morning) cortisol performed within 28 days prior to randomization to obtain a baseline value. Patients with abnormal TSH or AM cortisol baseline levels should be further evaluated and managed per institutional standards. Asymptomatic patients who require initiation or adjustment of medication or are followed without initiating treatment based on endocrinologist's recommendations are eligible.

• LVEF assessment must be performed within 42 days prior to randomization. (LVEF assessment performed by echocardiogram is preferred; however, MUGA scan may be substituted based on institutional preferences.) The LVEF must be = 55% regardless of the cardiac imaging facility's lower limit of normal.

• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab/placebo or 12 months after the last dose of chemotherapy.

• A woman is considered to be of childbearing potential if she is not postmenopausal, has not reached a postmenopausal state (= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).

• Examples of contraceptive methods with a failure rate of < 1% per year include:

bilateral tubal ligation; male partner sterilization; hormonal contraceptives that inhibit ovulation; hormone-releasing intrauterine devices; copper intrauterine devices.

• The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

• Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

• Excisional biopsy or lumpectomy performed prior to study entry.

• FNA alone to diagnose the breast cancer.

• Surgical axillary staging procedure prior to randomization. Exception: FNA or core biopsy of an axillary node is permitted for any patient. A pre-neoadjuvant therapy sentinel lymph node biopsy for patients with clinically negative axillary nodes is prohibited.

• Definitive clinical or radiologic evidence of metastatic disease.

• Previous history of contralateral invasive breast cancer. (Patients with synchronous and/or previous contralateral DCIS or LCIS are eligible.)

• Previous history of ipsilateral invasive breast cancer or ipsilateral DCIS. (Patients with synchronous or previous ipsilateral LCIS are eligible.)

• History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to study entry.

• Treatment including radiation therapy, chemotherapy, or targeted therapy, for the currently diagnosed breast cancer prior to randomization.

• Previous therapy with anthracyclines or taxanes for any malignancy.

• Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens. This includes but is not confined to:

• Active cardiac disease: angina pectoris that requires the use of anti-anginal medication; ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; valvular disease with documented compromise in cardiac function; or symptomatic pericarditis.

• History of cardiac disease: myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular function within 6 months prior to randomization; history of documented CHF; or documented cardiomyopathy.

• Uncontrolled hypertension defined as sustained systolic BP > 150 mmHg or diastolic BP > 90 mmHg. (Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.) Patients requiring = 3 BP medications are not eligible.

• History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.

• Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells.

• Known allergy or hypersensitivity to the components of the atezolizumab formulation.

• Known allergy or hypersensitivity to the components of the doxorubicin, epirubicin, cyclophosphamide, carboplatin, or paclitaxel formulations.

• Known allergy or hypersensitivity to liposomal or pegylated G-CSF formulations.

• Active or history of autoimmune disease or immune deficiency, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis for a more comprehensive list of autoimmune diseases and immune deficiencies) with the following exceptions:

• Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.

• Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.

• Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are permitted provided all of following conditions are met: Rash must cover < 10% of body surface area; Disease is well controlled at baseline and requires only low-potency topical corticosteroids; No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months.

• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.

• Patients known to be HIV positive.

• Active hepatitis B virus (HBV) infection, defined as having a positive hepatitis B surface antigen (HBsAg) test at screening. Patients with a past or resolved HBV infection, defined as having a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test at screening, are eligible for the study if active HBV infection is ruled out on the basis of HBV DNA viral load per local guidelines.

• Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test at screening confirmed by a polymerase chain reaction (PCR) positive for HCV RNA.

• Patients with clinically active tuberculosis.

• Severe infection within 28 days prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.

• Prior allogeneic stem cell or solid organ transplantation.

• Administration of a live, attenuated vaccine within 28 days prior to randomization or anticipation that such vaccine will be required during the study. Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within 28 days prior to randomization, during treatment or within 5 months following the last dose of atezolizumab/placebo.

• Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.

• Prior treatment with CD137 agonists or immune checkpoint-blockade therapies, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies.

• Treatment with systemic immunosuppressive medications (including but not limited to interferons, IL-2) within 28 days or 5 half-lives of the drug, whichever is longer, prior to randomization.

• Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis [anti-TNF] factor agents) within 14 days prior to randomization or anticipation of need for systemic immunosuppressive medications during the study.

• Nervous system disorder (paresthesias, peripheral motor neuropathy, or peripheral sensory neuropathy) = Grade 2, per the CTCAE v4.0.

• Symptomatic peripheral ischemia.

• Pregnancy or lactation at the time of randomization or intention to become pregnant during the study. (Note: Negative serum pregnancy test must be obtained within 14 days prior to randomization).

• Use of any investigational agent within 28 days prior to randomization.

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• Placebo
Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses. Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles. + placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used. Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose.
• Atezolizumab
Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses. Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles. + Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used. Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose.

Locations

Country	Name	City	State
Canada	Centre Hospitalier d'Universite de Montreal CHUM-Hotel Dieu	Montréal	Quebec
Canada	CIUSSS de l'Est-de-l'Ile-de-Montreal-Hopital-Maisonneuve-Rosemont	Montréal	Quebec
Canada	McGill University Health Centre-Cedars Cancer Centre	Montréal	Quebec
Canada	SMBD-Jewish General Hospital (MPSG)	Montréal	Quebec
Canada	CHU de Quebec-Hospital du Saint-Sacrement	Quebec City	Quebec
United States	New York Oncology Hematology PC	Albany	New York
United States	Aultman Alliance Cancer Center	Alliance	Ohio
United States	Kaiser Permanente-Anaheim	Anaheim	California
United States	Katmai Oncology Group	Anchorage	Alaska
United States	MRCC Auburn	Auburn	Washington
United States	Dell Seton Medical Center at the University of Texas-Seton Infusion Center	Austin	Texas
United States	Mount Sinai Comprehensive Cancer Center Aventura	Aventura	Florida
United States	Kaiser Permanente-Baldwin Park	Baldwin Park	California
United States	Greater Baltimore Medical Center	Baltimore	Maryland
United States	Harry and Jeanette Weinberg Cancer Center at Franklin Square	Baltimore	Maryland
United States	Medstar Union Memorial Hospital	Baltimore	Maryland
United States	UPMC Hillman Cancer Center-Beaver	Beaver	Pennsylvania
United States	Texas Oncology Bedford	Bedford	Texas
United States	Kaiser Permanente-Bellflower	Bellflower	California
United States	Maryland Oncology Hematology	Bethesda	Maryland
United States	Broome Oncolgy	Binghamton	New York
United States	Illinois Cancer Care-Bloomington	Bloomington	Illinois
United States	Maryland Oncology - Hematology Brandywine	Brandywine	Maryland
United States	Wellmont Medical Associates-Oncology and Hematology	Bristol	Virginia
United States	Henry Ford Cancer Institute Brownstown	Brownstown	Michigan
United States	Aurora Cancer Care-Southern Lakes	Burlington	Wisconsin
United States	Aultman Hospital	Canton	Ohio
United States	Aultman Medical Group Hematology and Oncology	Canton	Ohio
United States	Texas Oncology Carrollton	Carrollton	Texas
United States	RHOA of Cary	Cary	North Carolina
United States	Waverly Hematology Oncology	Cary	North Carolina
United States	Mercy Medical Center Hall-Perrine Cancer Center	Cedar Rapids	Iowa
United States	Cancer Center of Kansas - Chanute	Chanute	Kansas
United States	CAMC Health Education and Research Institute	Charleston	West Virginia
United States	Carolinas Medical Center-Levine Cancer Insitute	Charlotte	North Carolina
United States	Levine Cancer Center Institute Pineville	Charlotte	North Carolina
United States	John H. Stroger, Jr. Hospital of Cook County	Chicago	Illinois
United States	Rush University Medical Center	Chicago	Illinois
United States	Affiliated Oncologists	Chicago Ridge	Illinois
United States	Henry Ford Cancer Institute Macomb Hospital	Clinton Township	Michigan
United States	Arrowhead Regional Medical Center	Colton	California
United States	Maryland Oncology - Hematology PA	Columbia	Maryland
United States	University of Missouri-Ellis Fischel Cancer Center	Columbia	Missouri
United States	The Ohio State University Wexner Medical Center-Investigational Drug Service Oncology	Columbus	Ohio
United States	The Stephanie Speilman Comprehensive Breast Center	Columbus	Ohio
United States	UPMC Hillman Cancer Center - Passavant North	Cranberry Township	Pennsylvania
United States	Texas Oncology - Medical City Dallas	Dallas	Texas
United States	Texas Oncology - Methodist Dallas Cancer Center	Dallas	Texas
United States	Texas Oncology Dallas Presbyterian Hospital	Dallas	Texas
United States	Henry Ford Medical Center Fairlane	Dearborn	Michigan
United States	Cancer Care Specialists of Central Illinois	Decatur	Illinois
United States	Decatur Memorial Hospital	Decatur	Illinois
United States	Texas Oncology Denton	Denton	Texas
United States	Henry Ford Hospital	Detroit	Michigan
United States	Cancer Center of Kansas - Dodge City	Dodge City	Kansas
United States	City of Hope	Duarte	California
United States	Gwinnett Hospital System Center for Cancer Care	Duluth	Georgia
United States	Michigan State University	East Lansing	Michigan
United States	Crossroads Cancer Center	Effingham	Illinois
United States	Susan B. Allen Memorial Hosptial	El Dorado	Kansas
United States	Emhurst Memorial Nancy W. Knowles Cancer Center	Elmhurst	Illinois
United States	Ephrata Cancer Center	Ephrata	Pennsylvania
United States	Allegheny Cancer Institute St. Vincent	Erie	Pennsylvania
United States	St. Vincent Hospital	Erie	Pennsylvania
United States	Willamette Valley Cancer Institute and Research Center	Eugene	Oregon
United States	Sanford Roger Maris Cancer Center	Fargo	North Dakota
United States	UPMC Cancer Center Horizon	Farrell	Pennsylvania
United States	Texas Oncology Flower Mound	Flower Mound	Texas
United States	Aurora Health Center Fond du Lac	Fond Du Lac	Wisconsin
United States	Kaiser Permanente-Fontana	Fontana	California
United States	Fort Wayne Medical Oncology and Hematology Inc (Parkview Plaza)	Fort Wayne	Indiana
United States	Fort Wayne Medical Oncology and Hematology Inc (W. Jefferson Blvd)	Fort Wayne	Indiana
United States	Maryland Oncology - Hematology Frederick	Frederick	Maryland
United States	Illinois Cancer Care-Galesburg	Galesburg	Illinois
United States	RHOA of Garner	Garner	North Carolina
United States	Aurora Cancer Care-Germantown Health Center	Germantown	Wisconsin
United States	Wellspan Medical Oncology	Gettysburg	Pennsylvania
United States	MRCC Gig Harbor	Gig Harbor	Washington
United States	Aurora Cancer Care-Grafton	Grafton	Wisconsin
United States	Aurora BayCare Medical Center	Green Bay	Wisconsin
United States	UPMC Hillman Cancer Center- Mountain View	Greensburg	Pennsylvania
United States	UPMC Cancer Center Greenville	Greenville	Pennsylvania
United States	Gibbs Cancer Center and Research Institute - Pelham	Greer	South Carolina
United States	Meritus Center for Clinical Research	Hagerstown	Maryland
United States	Kaiser Permanente-Harbor City	Harbor City	California
United States	UNC Regional Physicians Hematology and Oncolgoy	High Point	North Carolina
United States	Memorial Healthcare System Office of Human Research	Hollywood	Florida
United States	Baylor College of Medicine	Houston	Texas
United States	Harris Health System-Smith Clinic	Houston	Texas
United States	Houston Methodist Cancer Center	Houston	Texas
United States	Cancer Center at Mercy - W. Laurel	Independence	Kansas
United States	Kaiser Permanente-Irvine	Irvine	California
United States	Henry Ford Allegiance Health	Jackson	Michigan
United States	AHN Cancer Institute at Jefferson	Jefferson Hills	Pennsylvania
United States	Broome Oncology	Johnson City	New York
United States	Wellmont Cancer Institute	Johnson City	Tennessee
United States	St. Bernard's Medical Center	Jonesboro	Arkansas
United States	Ochsner Medical Center-Kenner	Kenner	Louisiana
United States	Aurora Cancer Care-Kenosha South	Kenosha	Wisconsin
United States	Kingman Community Hospital	Kingman	Kansas
United States	Wellmont Cancer Institute	Kingsport	Tennessee
United States	Maryland Oncology - Hematology PA	Lanham	Maryland
United States	Michigan State University-Breslin Cancer Center	Lansing	Michigan
United States	Gwinnett Hospital System Center for Cancer Care	Lawrenceville	Georgia
United States	Seechler Family Cancer Center	Lebanon	Pennsylvania
United States	Virginia Cancer Care Specialist	Leesburg	Virginia
United States	Southwest Medical Center	Liberal	Kansas
United States	Cancer and Blood Specialty Clinic	Los Alamitos	California
United States	Kaiser Permanente-Sunset	Los Angeles	California
United States	Kaiser Permanente-West Los Angeles	Los Angeles	California
United States	Baptist Health Louisville; Consultants in Blood Disorders and Cancer	Louisville	Kentucky
United States	Norton Cancer Institute-Brownsboro	Louisville	Kentucky
United States	Norton Cancer Institute-Downtown	Louisville	Kentucky
United States	Norton Cancer Institute-Norton Healthcare Pavilion	Louisville	Kentucky
United States	Norton Cancer Institute-St Matthews	Louisville	Kentucky
United States	University of Louisville-James Graham Brown Cancer Center	Louisville	Kentucky
United States	Centra Lynchburg Hematology Oncology	Lynchburg	Virginia
United States	West Jefferson Medical Center Cancer Center	Marrero	Louisiana
United States	Texas Oncology - McAllen South Second	McAllen	Texas
United States	McPherson Center for Health	McPherson	Kansas
United States	Bon Secours Richmond Community Hospital Medical Oncology Associates at Memorial Regional Medical Center	Mechanicsville	Virginia
United States	Mount Sinai Comprehensive Cancer Center	Miami Beach	Florida
United States	Texas Oncology Midland Allison Cancer Center	Midland	Texas
United States	Bon Secours St Francis Medical Center	Midlothian	Virginia
United States	Aurora Cancer Care	Milwaukee	Wisconsin
United States	Aurora Cancer Care-Milwaukee South	Milwaukee	Wisconsin
United States	Aurora Sinai Medical Center	Milwaukee	Wisconsin
United States	Aurora St. Lukes Medical Center-Pharmacy Only	Milwaukee	Wisconsin
United States	Aurora West Allis Medical Center	Milwaukee	Wisconsin
United States	University of South Alabama Mitchell Cancer Institute	Mobile	Alabama
United States	Forbes Regional Hospital	Monroeville	Pennsylvania
United States	UPMC Hillman Cancer Center UPMC East-Monroeville	Monroeville	Pennsylvania
United States	West Virginia University	Morgantown	West Virginia
United States	UPMC Hillman Cancer Center Norwin	N. Huntingdon	Pennsylvania
United States	Edward Cancer Center	Naperville	Illinois
United States	UPMC Hillman Cancer Center New Castle	New Castle	Pennsylvania
United States	Ochsner Medical Center	New Orleans	Louisiana
United States	University Medical Center New Orleans	New Orleans	Louisiana
United States	Newark Beth Israel Medical Center	Newark	New Jersey
United States	Newton Medical Center	Newton	Kansas
United States	Southwest Virginia Regional Cancer Center	Norton	Virginia
United States	Henry Ford Medical Center Columbus	Novi	Michigan
United States	UF Health Cancer Center at Orlando Health	Orlando	Florida
United States	Vince Lombardi Cancer Clinic Oshkosh	Oshkosh	Wisconsin
United States	Illinois Cancer Care-Ottawa	Ottawa	Illinois
United States	Kaiser Permanente-Panorama City	Panorama City	California
United States	St. Bernard's Medical Center	Paragould	Arkansas
United States	Labette Health	Parsons	Kansas
United States	Illinois Cancer Care PC	Peoria	Illinois
United States	Illinois Cancer Care-Peru	Peru	Illinois
United States	FirstHealth of the Carolinas FirstHealth Outpatient Cancer Center	Pinehurst	North Carolina
United States	Allegheny General Hospital	Pittsburgh	Pennsylvania
United States	Magee-Women's Hospital of Pittsburgh	Pittsburgh	Pennsylvania
United States	UPCI Investigational Drug Services	Pittsburgh	Pennsylvania
United States	UPMC Hillman Cancer Center @ Passavant - HOA	Pittsburgh	Pennsylvania
United States	UPMC Hillman Cancer Center @ Passavant - OHA	Pittsburgh	Pennsylvania
United States	UPMC Hillman Cancer Center-Upper Saint Clair	Pittsburgh	Pennsylvania
United States	Western Pennsylvania Hospital	Pittsburgh	Pennsylvania
United States	WPAON at AGH	Pittsburgh	Pennsylvania
United States	WPAON at WPH	Pittsburgh	Pennsylvania
United States	Berkshire Hematology Oncology Services at Berkshire Medical Center Cancer and Infusion Center	Pittsfield	Massachusetts
United States	Edward Cancer Center Plainfield	Plainfield	Illinois
United States	Texas Oncology Plano	Plano	Texas
United States	Kaiser Permanente Northwest-Oncology/Hematology	Portland	Oregon
United States	Health Quest Medical Practice	Poughkeepsie	New York
United States	Vassar Brothers Medical Center	Poughkeepsie	New York
United States	Pratt Regional Medical Center	Pratt	Kansas
United States	Women's and Infants Hospital	Providence	Rhode Island
United States	MRCC Puyallup	Puyallup	Washington
United States	Aurora Cancer Care-Racine	Racine	Wisconsin
United States	RCC of Wakefield	Raleigh	North Carolina
United States	Rex Cancer Center	Raleigh	North Carolina
United States	RHOA of Blue Ridge	Raleigh	North Carolina
United States	Bon Secours Richmond Community Hospital Oncology Associates at St. Mary's Hospital	Richmond	Virginia
United States	Kaiser Permanente-Riverside	Riverside	California
United States	Maryland Oncology Hematology	Rockville	Maryland
United States	Nash UNC Health Care - Danny Talbott Cancer Center	Rocky Mount	North Carolina
United States	Cancer Center of Kansas - Salina	Salina	Kansas
United States	Kaiser Permanente - Otay	San Diego	California
United States	Kaiser Permanente Medical Group	San Diego	California
United States	Kaiser Permanente-Zion	San Diego	California
United States	Kaiser Permanente- San Marcos	San Marcos	California
United States	UPMC Cancer Center Northwest	Seneca	Pennsylvania
United States	Vince Lombardi Cancer Clinic Sheboygan	Sheboygan	Wisconsin
United States	Capital Hematology Oncology Associates	Silver Spring	Maryland
United States	Holy Cross Hospital	Silver Spring	Maryland
United States	Avera Cancer Institute	Sioux Falls	South Dakota
United States	Avera Cancer Institute-Sioux Falls	Sioux Falls	South Dakota
United States	Sanford Cancer Center Oncology Clinic	Sioux Falls	South Dakota
United States	Gwinnett Hospital System Center for Cancer Care	Snellville	Georgia
United States	City of Hope - South Pasadena	South Pasadena	California
United States	Spartanburg Medical Center	Spartanburg	South Carolina
United States	Aurora Medical Center in Summit	Summit	Wisconsin
United States	Cancer Care Specialists of Central Illinois-Swansea	Swansea	Illinois
United States	MultiCare Health System	Tacoma	Washington
United States	MultiCare Institute for Research & Innovation	Tacoma	Washington
United States	Texas Oncology - The Woodlands	The Woodlands	Texas
United States	Northwest Cancer Specialists	Tigard	Oregon
United States	Torrance Memorial Physician Network	Torrance	California
United States	University of Maryland, St. Joseph Medical Center	Towson	Maryland
United States	Vince Lombardi Cancer Clinic-Two Rivers	Two Rivers	Wisconsin
United States	UPMC Hillman Cancer Center - Uniontown	Uniontown	Pennsylvania
United States	City of Hope - Upland	Upland	California
United States	MD Anderson Cancer Center at Cooper	Voorhees	New Jersey
United States	UPMC Hillman Cancer Center-Washington	Washington	Pennsylvania
United States	Aurora Cancer Care	Wauwatosa	Wisconsin
United States	Henry Ford Hospital W Bloomfield	West Bloomfield	Michigan
United States	Wexford Health & Wellness Pavilion	Wexford	Pennsylvania
United States	Maryland Oncology Hematology	Wheaton	Maryland
United States	PIH Health	Whittier	California
United States	Cancer Center of Kansas	Wichita	Kansas
United States	Cancer Center of Kansas - Wichita	Wichita	Kansas
United States	Winfield Healthcare Center	Winfield	Kansas
United States	Kaiser Permanente-Woodland Hills	Woodland Hills	California
United States	Henry Ford Cancer Institute Wyandotte Hospital	Wyandotte	Michigan
United States	Cancer Care Associates of York	York	Pennsylvania
United States	Wellspan Health-York Cancer Center Oncology Research	York	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
NSABP Foundation Inc	Genentech, Inc., Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Event-free survival (EFS)	Time from randomization until event	From randomization until event, through study follow up to the time target number of events is obtained, up to 5 years
Secondary	Overall survival (OS)	Time from randomization until death from any cause	From date of randomization through study follow-up, to the time the target number of events is obtained, up to 5 years
Secondary	Pathologic complete response in the breast and lymph nodes (ypT0/Tis ypN0)	Absence of any invasive component in the resected breast specimen and all resected lymph nodes	Following completion of neoadjuvant therapy (ypT0/Tis ypN0)
Secondary	Distant disease-free survival (DDFS)	Time from randomization until distant recurrence, death from breast cancer, death from other causes, and second primary invasive cancer (non-breast)	From date of randomization through study follow-up, to the time the target number of events is obtained, up to 5 years
Secondary	Disease-free survival (DFS)	Ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, ipsilateral or contralateral DCIS, second primary non-breast invasive cancer and death attributable to any cause including breast cancer, non-breast cancer, or unknown cause.	From the first breast surgical procedure to the first disease recurrence or death from any cause
Secondary	Frequency of Adverse Events	Frequency of adverse events graded according to the NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)	From beginning of study therapy to 90 days after last dose of study therapy
Secondary	Frequency of immune Adverse Events of Special Interest	Frequency of immune adverse events of special interest according to the NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)	From beginning of study therapy to 90 days after last dose of study therapy
Secondary	Cardiac safety lead-in (Troponin-T)	Troponin-T levels in blood prior to initial dose of AC/EC following completion of carboplatin/paclitaxel co-administered with atezolizumab/placebo	prior to initial dose of AC/EC following completion of carboplatin/paclitaxel co-administered with atezolizumab/placebo, approximately 12 weeks
Secondary	Cardiac safety lead-in (Troponin-T)	Troponin-T levels in blood after administration of the 1st cycle of AC/EC prior to administration of atezolizumab/placebo	After administration of the 1st dose of AC/EC prior to administration of atezolizumab/placebo, approximately 1 hour after beginning the 1st dose of AC/EC
Secondary	Cardiac safety lead-in (Troponin-T)	Troponin-T levels in blood after administration of the 3rd cycle of AC/EC prior to administration of atezolizumab/placebo	After administration of the 3rd dose (Cycle 3; each cycle is 21 days) of AC/EC prior to administration of atezolizumab/placebo, approximately 1 hour after beginning the 3rd dose of AC/EC
Secondary	Cardiac safety lead-in (Left ventricular ejection fraction; LVEF)	LVEF levels measured at baseline prior to initiation of carboplatin/paclitaxel and atezolizumab/placebo	Prior to initiation of carboplatin/paclitaxel and atezolizumab/placebo, at baseline
Secondary	Cardiac safety lead-in (Left ventricular ejection fraction; LVEF)	LVEF levels measured before 3rd cycle of AC/EC	Prior to the 3rd cycle (each cycle is every 21 days) of AC/EC, approximately 6 weeks after initiation of AC/EC
Secondary	Cardiac safety lead-in (Left ventricular ejection fraction; LVEF)	LVEF levels measured after surgery	Four to 6 weeks after surgery